|
시장보고서
상품코드
2039013
듀테트라베나진(Deutetrabenazine) 시장 : 적응증별, 제형별, 최종사용자별, 유통 채널별, 지역별Deutetrabenazine Market, By Indication, By Formulation Type, By End User, By Distribution Channel, By Geography |
||||||
듀테트라베나진 시장은 2026년에 10억 8,000만 달러로 추정되며, 2033년까지 18억 8,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.24%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 10억 8,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 8.24% | 2033년 시장 규모 예측: | 18억 8,000만 달러 |
듀테트라베나진은 헌팅턴병 및 지연성 운동 이상증과 같은 인간의 신경학적 운동 장애를 관리하는 데 있어 주요한 치료적 진전으로 인정받고 있습니다.
듀테트라베나진은 소낭성 모노아민 수송체 2(VMT2)의 선택적 억제제로서 효능을 나타내며, 테트라베나딘과 같은 다른 약물에 비해 더 우수한 효능과 내약성, 그리고 부작용 발생 빈도를 낮춥니다. 듀테트라베나진의 도입으로 과운동성 운동장애 관리를 위한 표적 치료 옵션이 강화되어 그동안 충족되지 못했던 미충족 수요를 일부 충족시킬 수 있게 됐습니다. 그 결과, 희귀 신경질환에 대한 인식이 높아지고 진단법이 발전하면서 진단을 받는 환자 수가 증가하고 있습니다.
세계 듀테트라베나진 시장은 희귀질환 치료제(희귀의약품) 치료와 정밀의료의 개발이 점점 더 중요해지고 있는 가운데, 신경학 치료제 부문에서 중요한 틈새시장으로 볼 수 있습니다. 이 시장에서는 환자층의 다양한 요구에 대응하기 위해 다양한 제형과 용량의 제품이 제공되고 있습니다. 승인 상황, 의료 인프라의 발전, 의사의 인식, 환자 접근 프로그램 개선 등 다양한 요인이 시장에 영향을 미치고 있습니다. 이러한 요인들은 운동장애에 대한 핵심 치료 옵션으로서 이 약의 사업 전개에 기여하고 있습니다.
시장 역학
세계 듀테트라베나진 시장은 주로 헌팅턴병과 지연성 운동 이상증의 유병률 증가와 유전자 검사 및 신경학적 평가 방법의 개선으로 인한 진단 방법의 개선에 의해 주도되고 있습니다. 의료진들 사이에서 듀테트라베나진이 환자의 1차 치료제로서 효과적이라는 인식이 높아지면서 세계 듀테트라베나진 시장을 주도하고 있습니다.
듀테트라베나진의 사용 확대는 선진국의 상환 정책에 의해 촉진되고 있습니다. 안전성 프로파일에 대한 임상적 증거의 증가와 다른 치료법 대비 듀테트라베나진의 사용 빈도가 증가함에 따라 치료 결과 개선과 환자 순응도 향상으로 이어져 세계 듀테트라베나진 시장의 성장을 견인하고 있습니다.
이러한 장점에도 불구하고 시장은 몇 가지 도전에 직면해 있습니다. 예를 들어, 높은 치료비용을 들 수 있는데, 가격에 민감한 시장이나 개발도상국 시장에서는 가격 측면에서 접근성을 제한하는 요인으로 작용하고 있습니다. 또한, 일차 진료의사의 희귀 신경질환에 대한 인식 부족과 운동장애 진단의 어려움은 치료 시작의 속도를 제한하는 요인으로 작용하고 있습니다. 희귀질환 환자 수가 적고, 엄격한 규제 또한 시장 침투 속도를 제한하는 요인으로 작용하고 있습니다.
그러나 신흥시장의 의료 인프라와 의료비 증가라는 배경을 감안할 때, 성장 기회는 매우 크다고 할 수 있습니다. 시장의 혁신이 향후 시장을 견인할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 듀테트라베나진 시장의 주요 기업 프로파일을 프로파일링합니다 : 회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 듀테트라베나진 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 듀테트라베나진 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 듀테트라베나진 시장 : 적응증별, 2021-2033년
제5장 세계의 듀테트라베나진 시장 : 제형별, 2021-2033년
제6장 세계의 듀테트라베나진 시장 : 최종사용자별, 2021-2033년
제7장 세계의 듀테트라베나진 시장 : 유통 채널별, 2021-2033년
제8장 세계의 듀테트라베나진 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 추천
제11장 참고문헌 및 조사 방법
KSM 26.06.04Deutetrabenazine Market is estimated to be valued at USD 1.08 Bn in 2026 and is expected to reach USD 1.88 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.24% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.08 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.24% | 2033 Value Projection: | USD 1.88 Bn |
Deutetrabenazine has been identified as a major therapeutic advancement in the management of human neurological movement disorders such as Huntington's disease and tardive dyskinesia.
Deutetrabenazine has shown efficacy in its use as a selective inhibitor of the vesicular monoamine transporter 2, offering better efficacy and tolerability at a reduced frequency compared to other drugs such as tetrabenazine. The introduction of deutetrabenazine has reinforced the armamentarium of targeted therapies for the management of hyperkinetic movement disorders, meeting some of the hitherto unmet clinical needs. As a result, the growing awareness of rare neurological disorders, along with improvements in diagnostic methods, has led to an increase in the number of patients diagnosed.
The global deutetrabenazine market can be considered a significant niche market for the neurology therapeutics segment, with the growing emphasis on the development of orphan drug therapies and precision medicine. The market is served by various formulations and strengths of the drug to address the different needs of the patient population. Various factors affect the market, including approvals, advances in healthcare infrastructure, awareness among physicians, and improved patient access programs. These factors contribute to the business development of the drug as a backbone treatment option for movement disorders.
Market Dynamics
The global deutetrabenazine market is primarily driven by the rise in the prevalence of Huntington's disease and tardive dyskinesia, and the improvement in diagnostic methods due to better genetic testing and neurological assessment methods. The rise in awareness among medical professionals about the effectiveness of deutetrabenazine as a first-line treatment for patients is driving the global deutetrabenazine market.
The increasing use of deutetrabenazine is supplemented by the reimbursement policies of developed countries. The rise in clinical evidence of the safety profile and the frequency of use of deutetrabenazine compared to other treatments is driving the global deutetrabenazine market due to better outcomes and better compliance among patients.
Despite these advantages, the market is facing some challenges, such as the high cost of treatment, which is limiting the market in terms of accessibility in price-sensitive and developing markets. In addition, a lack of awareness of rare neurological disorders among primary care physicians and the difficulty of diagnosing movement disorders are limiting the market in terms of the speed of treatment initiation. The small population of patients with orphan diseases and the stringent regulations are also limiting the market in terms of speed of the market penetration.
However, the opportunities for growth are significant in the context of the emerging markets and the increasing healthcare infrastructure and expenditure in these markets. The innovations in the market are expected to boost the market in the future.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global deutetrabenazine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Teva Pharmaceutical Industries, Neurocrine Biosciences, Bausch Health Companies, H. Lundbeck, Intas Pharmaceuticals, Upsher-Smith Laboratories, Dr. Reddy's Laboratories, Lupin, Apotex, and Viatris
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global deutetrabenazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global deutetrabenazine market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Tardive Dyskinesia (TD)
- Huntington's Disease Chorea
- Formulation Type Insights (Revenue, USD Bn, 2021 - 2033)
- Immediate-Release (IR)
- Extended-Release (XR)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Teva Pharmaceutical Industries
- Neurocrine Biosciences
- Bausch Health Companies
- Lundbeck
- Intas Pharmaceuticals
- Upsher-Smith Laboratories
- Reddy's Laboratories
- Lupin
- Apotex
- Viatris
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Deutetrabenazine Market, By Indication
- Global Deutetrabenazine Market, By Formulation Type
- Global Deutetrabenazine Market, By End User
- Global Deutetrabenazine Market, By Distribution Channel
- Global Deutetrabenazine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Deutetrabenazine Market, By Indication, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tardive Dyskinesia (TD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Huntington's Disease Chorea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Deutetrabenazine Market, By Formulation Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Immediate-Release (IR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Extended-Release (XR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Deutetrabenazine Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Deutetrabenazine Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Deutetrabenazine Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Neurocrine Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Upsher Smith Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
